VDR_HUMAN
ID VDR_HUMAN Reviewed; 427 AA.
AC P11473; B2R5Q1; G3V1V9; Q5PSV3;
DT 01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT 01-OCT-1989, sequence version 1.
DT 03-AUG-2022, entry version 248.
DE RecName: Full=Vitamin D3 receptor;
DE Short=VDR;
DE AltName: Full=1,25-dihydroxyvitamin D3 receptor;
DE AltName: Full=Nuclear receptor subfamily 1 group I member 1;
GN Name=VDR; Synonyms=NR1I1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=2835767; DOI=10.1073/pnas.85.10.3294;
RA Baker A.R., McDonnell D.P., Hughes M., Crisp T.M., Mangelsdorf D.J.,
RA Haussler M.R., Pike J.W., Shine J., O'Malley B.W.;
RT "Cloning and expression of full-length cDNA encoding human vitamin D
RT receptor.";
RL Proc. Natl. Acad. Sci. U.S.A. 85:3294-3298(1988).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=1324736; DOI=10.1016/0167-4781(92)90063-6;
RA Goto H., Chen K.S., Prahl J.M., Deluca H.F.;
RT "A single receptor identical with that from intestine/T47D cells mediates
RT the action of 1,25-dihydroxyvitamin D-3 in HL-60 cells.";
RL Biochim. Biophys. Acta 1132:103-108(1992).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC TISSUE=Lens epithelium;
RA Rae J.L., Shepard A.R.;
RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=9212063; DOI=10.1210/mend.11.8.9951;
RA Miyamoto K., Kesterson R.A., Yamamoto H., Taketani Y., Nishiwaki E.,
RA Tatsumi S., Inoue Y., Morita K., Takeda E., Pike J.W.;
RT "Structural organization of the human vitamin D receptor chromosomal gene
RT and its promoter.";
RL Mol. Endocrinol. 11:1165-1179(1997).
RN [5]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-230 AND ILE-362.
RG NIEHS SNPs program;
RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [7]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16541075; DOI=10.1038/nature04569;
RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA Gibbs R.A.;
RT "The finished DNA sequence of human chromosome 12.";
RL Nature 440:346-351(2006).
RN [8]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA Hunkapiller M.W., Myers E.W., Venter J.C.;
RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN [9]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC TISSUE=Placenta;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [10]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 24-90 (ISOFORM 1/2).
RC TISSUE=Peripheral blood;
RX PubMed=1850412; DOI=10.1016/s0021-9258(20)89488-5;
RA Yu X.-P., Mocharla H., Hustmyer F.G., Manolagas S.C.;
RT "Vitamin D receptor expression in human lymphocytes. Signal requirements
RT and characterization by western blots and DNA sequencing.";
RL J. Biol. Chem. 266:7588-7595(1991).
RN [11]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 343-427.
RX PubMed=16252240; DOI=10.1086/497438;
RA Fang Y., van Meurs J.B., d'Alesio A., Jhamai M., Zhao H., Rivadeneira F.,
RA Hofman A., van Leeuwen J.P., Jehan F., Pols H.A., Uitterlinden A.G.;
RT "Promoter and 3'-untranslated-region haplotypes in the vitamin D receptor
RT gene predispose to osteoporotic fracture: the Rotterdam study.";
RL Am. J. Hum. Genet. 77:807-823(2005).
RN [12]
RP INTERACTION WITH NCOA3.
RX PubMed=9267036; DOI=10.1016/s0092-8674(00)80516-4;
RA Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L.,
RA Privalsky M.L., Nakatani Y., Evans R.M.;
RT "Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and
RT forms a multimeric activation complex with P/CAF and CBP/p300.";
RL Cell 90:569-580(1997).
RN [13]
RP INTERACTION WITH SNW1.
RX PubMed=9632709; DOI=10.1074/jbc.273.26.16434;
RA Baudino T.A., Kraichely D.M., Jefcoat S.C. Jr., Winchester S.K.,
RA Partridge N.C., Macdonald P.N.;
RT "Isolation and characterization of a novel coactivator protein, NCoA-62,
RT involved in vitamin D-mediated transcription.";
RL J. Biol. Chem. 273:16434-16441(1998).
RN [14]
RP INTERACTION WITH NCOA6.
RX PubMed=10866662; DOI=10.1128/mcb.20.14.5048-5063.2000;
RA Mahajan M.A., Samuels H.H.;
RT "A new family of nuclear receptor coregulators that integrates nuclear
RT receptor signaling through CBP.";
RL Mol. Cell. Biol. 20:5048-5063(2000).
RN [15]
RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF 47-PHE-PHE-48.
RX PubMed=12145331; DOI=10.1210/me.2001-0345;
RA Pruefer K., Barsony J.;
RT "Retinoid X receptor dominates the nuclear import and export of the
RT unliganded vitamin D receptor.";
RL Mol. Endocrinol. 16:1738-1751(2002).
RN [16]
RP RETRACTED PAPER.
RX PubMed=16252006; DOI=10.1038/sj.emboj.7600853;
RA Fujiki R., Kim M.-S., Sasaki Y., Yoshimura K., Kitagawa H., Kato S.;
RT "Ligand-induced transrepression by VDR through association of WSTF with
RT acetylated histones.";
RL EMBO J. 24:3881-3894(2005).
RN [17]
RP RETRACTION NOTICE OF PUBMED:16252006.
RX PubMed=25452584; DOI=10.15252/embj.201470110;
RA Fujiki R., Kim M.-S., Sasaki Y., Yoshimura K., Kitagawa H., Kato S.;
RT "Retraction: 'Ligand-induced transrepression by VDR through association of
RT WSTF with acetylated histones'.";
RL EMBO J. 33:2881-2881(2014).
RN [18]
RP SUBCELLULAR LOCATION.
RX PubMed=16207705; DOI=10.1074/jbc.m509347200;
RA Miyauchi Y., Michigami T., Sakaguchi N., Sekimoto T., Yoneda Y., Pike J.W.,
RA Yamagata M., Ozono K.;
RT "Importin 4 is responsible for ligand-independent nuclear translocation of
RT vitamin D receptor.";
RL J. Biol. Chem. 280:40901-40908(2005).
RN [19]
RP INTERACTION WITH IRX4.
RC TISSUE=Prostate;
RX PubMed=22323358; DOI=10.1093/hmg/dds025;
RA Nguyen H.H., Takata R., Akamatsu S., Shigemizu D., Tsunoda T., Furihata M.,
RA Takahashi A., Kubo M., Kamatani N., Ogawa O., Fujioka T., Nakamura Y.,
RA Nakagawa H.;
RT "IRX4 at 5p15 suppresses prostate cancer growth through the interaction
RT with vitamin D receptor, conferring prostate cancer susceptibility.";
RL Hum. Mol. Genet. 21:2076-2085(2012).
RN [20]
RP 9AATAD MOTIF.
RX PubMed=30468856; DOI=10.1016/j.jsbmb.2018.11.008;
RA Piskacek M., Havelka M., Jendruchova K., Knight A.;
RT "Nuclear hormone receptors: Ancient 9aaTAD and evolutionally gained NCoA
RT activation pathways.";
RL J. Steroid Biochem. Mol. Biol. 187:118-123(2019).
RN [21]
RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 118-427 IN COMPLEX WITH
RP DIHYDROXYVITAMIN D3, IDENTIFICATION BY MASS SPECTROMETRY, AND FUNCTION.
RX PubMed=10678179; DOI=10.1016/s1097-2765(00)80413-x;
RA Rochel N., Wurtz J.-M., Mitschler A., Klaholz B., Moras D.;
RT "The crystal structure of the nuclear receptor for vitamin D bound to its
RT natural ligand.";
RL Mol. Cell 5:173-179(2000).
RN [22]
RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 118-427 IN COMPLEXES WITH VITAMIN
RP D3 AND VITAMIN D3 ANALOGS.
RX PubMed=11344298; DOI=10.1073/pnas.091018698;
RA Tocchini-Valentini G., Rochel N., Wurtz J.-M., Mitschler A., Moras D.;
RT "Crystal structures of the vitamin D receptor complexed to superagonist 20-
RT epi ligands.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:5491-5496(2001).
RN [23]
RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 16-125 IN COMPLEX WITH DNA,
RP MUTAGENESIS OF 61-PRO-PHE-62 AND HIS-75, AND SUBUNIT.
RX PubMed=11980721; DOI=10.1093/emboj/21.9.2242;
RA Shaffer P.L., Gewirth D.T.;
RT "Structural basis of VDR-DNA interactions on direct repeat response
RT elements.";
RL EMBO J. 21:2242-2252(2002).
RN [24]
RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 188-427 IN COMPLEXES WITH VITAMIN
RP D3 ANALOGS.
RX PubMed=15055995; DOI=10.1021/jm0310582;
RA Tocchini-Valentini G., Rochel N., Wurtz J.-M., Moras D.;
RT "Crystal structures of the vitamin D nuclear receptor liganded with the
RT vitamin D side chain analogues calcipotriol and seocalcitol, receptor
RT agonists of clinical importance. Insights into a structural basis for the
RT switching of calcipotriol to a receptor antagonist by further side chain
RT modification.";
RL J. Med. Chem. 47:1956-1961(2004).
RN [25]
RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 16-125 OF MUTANT
RP ALA-61/ALA-62/ALA-75 IN COMPLEX WITH RXRA AND DNA, AND SUBUNIT.
RX PubMed=15225774; DOI=10.1016/j.jsbmb.2004.03.084;
RA Shaffer P.L., Gewirth D.T.;
RT "Structural analysis of RXR-VDR interactions on DR3 DNA.";
RL J. Steroid Biochem. Mol. Biol. 89:215-219(2004).
RN [26]
RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 188-427 IN COMPLEX WITH VITAMIN D3
RP ANALOG, IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH
RP NCOA1; NCOA2 AND MED1.
RX PubMed=15728261; DOI=10.1124/mol.104.008730;
RA Eelen G., Verlinden L., Rochel N., Claessens F., De Clercq P.,
RA Vandewalle M., Tocchini-Valentini G., Moras D., Bouillon R., Verstuyf A.;
RT "Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D
RT explained by vitamin D receptor-coactivator interaction.";
RL Mol. Pharmacol. 67:1566-1573(2005).
RN [27]
RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 188-427 IN COMPLEXES WITH
RP DIHYDROXYVITAMIN D3 AND VITAMIN D3 ANALOGS, AND FUNCTION.
RX PubMed=16913708; DOI=10.1021/jm0604070;
RA Hourai S., Fujishima T., Kittaka A., Suhara Y., Takayama H., Rochel N.,
RA Moras D.;
RT "Probing a water channel near the A-ring of receptor-bound 1 alpha,25-
RT dihydroxyvitamin D3 with selected 2 alpha-substituted analogues.";
RL J. Med. Chem. 49:5199-5205(2006).
RN [28]
RP VARIANTS VDDR2A ASP-33 AND GLN-73.
RX PubMed=2849209; DOI=10.1126/science.2849209;
RA Hughes M.R., Malloy P.J., Kieback D.G., Kesterson R.A., Pike J.W.,
RA Feldman D., O'Malley B.W.;
RT "Point mutations in the human vitamin D receptor gene associated with
RT hypocalcemic rickets.";
RL Science 242:1702-1705(1988).
RN [29]
RP VARIANT VDDR2A GLN-35.
RX PubMed=8381803; DOI=10.1210/jcem.76.2.8381803;
RA Yagi H., Ozono K., Miyake H., Nagashima K., Kuroume T., Pike J.W.;
RT "A new point mutation in the deoxyribonucleic acid-binding domain of the
RT vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-
RT resistant rickets.";
RL J. Clin. Endocrinol. Metab. 76:509-512(1993).
RN [30]
RP VARIANT VDDR2A GLN-50.
RX PubMed=1652893;
RA Saijo T., Ito M., Takeda E., Mahbubul Huq A.H.M., Naito E., Yokota I.,
RA Sone T., Pike J.W., Kuroda Y.;
RT "A unique mutation in the vitamin D receptor gene in three Japanese
RT patients with vitamin D-dependent rickets type II: utility of single-strand
RT conformation polymorphism analysis for heterozygous carrier detection.";
RL Am. J. Hum. Genet. 49:668-673(1991).
RN [31]
RP VARIANT VDDR2A GLN-80.
RX PubMed=2177843; DOI=10.1210/mend-4-4-623;
RA Sone T., Marx S.J., Liberman U.A., Pike J.W.;
RT "A unique point mutation in the human vitamin D receptor chromosomal gene
RT confers hereditary resistance to 1,25-dihydroxyvitamin D3.";
RL Mol. Endocrinol. 4:623-631(1990).
RN [32]
RP VARIANT VDDR2A GLN-80.
RX PubMed=8106618; DOI=10.1210/jcem.78.2.8106618;
RA Malloy P.J., Weisman Y., Feldman D.;
RT "Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from
RT a mutation in the vitamin D receptor deoxyribonucleic acid-binding
RT domain.";
RL J. Clin. Endocrinol. Metab. 78:313-316(1994).
RN [33]
RP VARIANTS VDDR2A 152-GLN--SER-427 DEL AND LEU-274.
RX PubMed=8392085; DOI=10.1172/jci116539;
RA Kristjansson K., Rut A.R., Hewison M., O'Riordan J.L.H., Hughes M.R.;
RT "Two mutations in the hormone binding domain of the vitamin D receptor
RT cause tissue resistance to 1,25 dihydroxyvitamin D3.";
RL J. Clin. Invest. 92:12-16(1993).
RN [34]
RP VARIANTS VDDR2A GLU-45 AND ILE-47.
RX PubMed=7828346; DOI=10.1111/j.1365-2265.1994.tb01822.x;
RA Rut A.R., Hewison M., Kristjansson K., Luisi B., Hughes M.R.,
RA O'Riordan J.L.H.;
RT "Two mutations causing vitamin D resistant rickets: modelling on the basis
RT of steroid hormone receptor DNA-binding domain crystal structures.";
RL Clin. Endocrinol. (Oxf.) 41:581-590(1994).
RN [35]
RP VARIANT VDDR2A ASP-46.
RX PubMed=8675579; DOI=10.1210/jcem.81.7.8675579;
RA Lin U.-T., Malloy P.J., Sakati N., Al-Ashwal A., Feldman D.;
RT "A novel mutation in the deoxyribonucleic acid-binding domain of the
RT vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant
RT rickets.";
RL J. Clin. Endocrinol. Metab. 81:2564-2569(1996).
RN [36]
RP VARIANTS VDDR2A SER-314 AND CYS-391.
RX PubMed=8961271; DOI=10.1210/mend.10.12.8961271;
RA Whitfield G.K., Selznick S.H., Haussler C.A., Hsieh J.-C., Galligan M.A.,
RA Jurutka P.W., Thompson P.D., Lee S.M., Zerwekh J.E., Haussler M.R.;
RT "Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin
RT D(3): point mutations confer reduced transactivation in response to ligand
RT and impaired interaction with the retinoid X receptor heterodimeric
RT partner.";
RL Mol. Endocrinol. 10:1617-1631(1996).
RN [37]
RP VARIANT VDDR2A GLN-305.
RX PubMed=9005998; DOI=10.1172/jci119158;
RA Malloy P.J., Eccleshall T.R., Gross C., van Maldergem L., Bouillon R.,
RA Feldman D.;
RT "Hereditary vitamin D resistant rickets caused by a novel mutation in the
RT vitamin D receptor that results in decreased affinity for hormone and
RT cellular hyporesponsiveness.";
RL J. Clin. Invest. 99:297-304(1997).
RN [38]
RP INVOLVEMENT IN MYCOBACTERIUM TUBERCULOSIS SUSCEPTIBILITY.
RX PubMed=15032981; DOI=10.1111/j.2004.00183.x;
RA Selvaraj P., Kurian S.M., Chandra G., Reetha A.M., Charles N.,
RA Narayanan P.R.;
RT "Vitamin D receptor gene variants of BsmI, ApaI, TaqI, and FokI
RT polymorphisms in spinal tuberculosis.";
RL Clin. Genet. 65:73-76(2004).
RN [39]
RP VARIANT VDDR2A MET-346.
RX PubMed=17970811; DOI=10.1111/j.1365-2133.2007.08232.x;
RA Arita K., Nanda A., Wessagowit V., Akiyama M., Alsaleh Q.A., McGrath J.A.;
RT "A novel mutation in the VDR gene in hereditary vitamin D-resistant
RT rickets.";
RL Br. J. Dermatol. 158:168-171(2008).
RN [40]
RP VARIANT VDDR2A PRO-360, CHARACTERIZATION OF VARIANT VDDR2A 152-GLN--SER-427
RP DEL; LEU-274; GLN-305; MET-346 AND PRO-360, FUNCTION, INTERACTION WITH
RP NCOA1; NCOR1 AND RXR, AND SUBCELLULAR LOCATION.
RX PubMed=28698609; DOI=10.1038/s41598-017-05081-x;
RA Tamura M., Ishizawa M., Isojima T., Oezen S., Oka A., Makishima M.,
RA Kitanaka S.;
RT "Functional analyses of a novel missense and other mutations of the vitamin
RT D receptor in association with alopecia.";
RL Sci. Rep. 7:5102-5102(2017).
CC -!- FUNCTION: Nuclear receptor for calcitriol, the active form of vitamin
CC D3 which mediates the action of this vitamin on cells (PubMed:28698609,
CC PubMed:16913708, PubMed:15728261, PubMed:10678179). Enters the nucleus
CC upon vitamin D3 binding where it forms heterodimers with the retinoid X
CC receptor/RXR (PubMed:28698609). The VDR-RXR heterodimers bind to
CC specific response elements on DNA and activate the transcription of
CC vitamin D3-responsive target genes (PubMed:28698609). Plays a central
CC role in calcium homeostasis (By similarity).
CC {ECO:0000250|UniProtKB:P13053, ECO:0000269|PubMed:10678179,
CC ECO:0000269|PubMed:15728261, ECO:0000269|PubMed:16913708,
CC ECO:0000269|PubMed:28698609}.
CC -!- SUBUNIT: Homodimer in the absence of bound vitamin D3
CC (PubMed:11980721). Heterodimer with RXRA after vitamin D3 binding
CC (PubMed:15225774, PubMed:11980721, PubMed:10678179). Interacts with
CC MED1, NCOA1, NCOA2, NCOA3 and NCOA6 coactivators, leading to a strong
CC increase of transcription of target genes (PubMed:10866662,
CC PubMed:15728261, PubMed:28698609, PubMed:9267036). Interacts with the
CC corepressor NCOR1 (PubMed:28698609). Interacts with SNW1
CC (PubMed:9632709). Interacts with IRX4, the interaction does not affect
CC its transactivation activity (PubMed:22323358). Interacts with CRY1 (By
CC similarity). Interacts with CRY2 in a ligand-dependent manner (By
CC similarity). {ECO:0000250|UniProtKB:P48281,
CC ECO:0000269|PubMed:10678179, ECO:0000269|PubMed:10866662,
CC ECO:0000269|PubMed:11980721, ECO:0000269|PubMed:15225774,
CC ECO:0000269|PubMed:15728261, ECO:0000269|PubMed:22323358,
CC ECO:0000269|PubMed:28698609, ECO:0000269|PubMed:9267036,
CC ECO:0000269|PubMed:9632709}.
CC -!- INTERACTION:
CC P11473; Q09472: EP300; NbExp=3; IntAct=EBI-286357, EBI-447295;
CC P11473; Q15648: MED1; NbExp=4; IntAct=EBI-286357, EBI-394459;
CC P11473; P50222: MEOX2; NbExp=3; IntAct=EBI-286357, EBI-748397;
CC P11473; Q15788: NCOA1; NbExp=3; IntAct=EBI-286357, EBI-455189;
CC P11473; P26045: PTPN3; NbExp=4; IntAct=EBI-286357, EBI-1047946;
CC P11473; P19793: RXRA; NbExp=6; IntAct=EBI-286357, EBI-78598;
CC P11473; Q13573: SNW1; NbExp=5; IntAct=EBI-286357, EBI-632715;
CC P11473; Q13501: SQSTM1; NbExp=4; IntAct=EBI-286357, EBI-307104;
CC P11473; P04637: TP53; NbExp=6; IntAct=EBI-286357, EBI-366083;
CC P11473; Q15645: TRIP13; NbExp=3; IntAct=EBI-286357, EBI-358993;
CC P11473; Q9JLI4: Ncoa6; Xeno; NbExp=2; IntAct=EBI-286357, EBI-286271;
CC P11473; P28700: Rxra; Xeno; NbExp=3; IntAct=EBI-286357, EBI-346715;
CC P11473-2; X5D778: ANKRD11; NbExp=3; IntAct=EBI-12874016, EBI-17183751;
CC P11473-2; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-12874016, EBI-741158;
CC P11473-2; Q01804: OTUD4; NbExp=3; IntAct=EBI-12874016, EBI-1054396;
CC P11473-2; Q96S38: RPS6KC1; NbExp=3; IntAct=EBI-12874016, EBI-347731;
CC P11473-2; P48443: RXRG; NbExp=4; IntAct=EBI-12874016, EBI-712405;
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407,
CC ECO:0000269|PubMed:12145331, ECO:0000269|PubMed:16207705,
CC ECO:0000269|PubMed:28698609}. Cytoplasm {ECO:0000269|PubMed:12145331,
CC ECO:0000269|PubMed:16207705, ECO:0000269|PubMed:28698609}.
CC Note=Localizes mainly to the nucleus (PubMed:28698609,
CC PubMed:12145331). Translocated into the nucleus via both ligand-
CC dependent and ligand-independent pathways; ligand-independent nuclear
CC translocation is mediated by IPO4 (PubMed:16207705).
CC {ECO:0000269|PubMed:12145331, ECO:0000269|PubMed:16207705,
CC ECO:0000269|PubMed:28698609}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=P11473-1; Sequence=Displayed;
CC Name=2;
CC IsoId=P11473-2; Sequence=VSP_047218;
CC -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a
CC DNA-binding domain and a C-terminal ligand-binding domain.
CC {ECO:0000269|PubMed:10678179}.
CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC number of yeast and animal transcription factors.
CC {ECO:0000305|PubMed:30468856}.
CC -!- POLYMORPHISM: Genetic variations in VDR may determine Mycobacterium
CC tuberculosis susceptibility [MIM:607948].
CC {ECO:0000269|PubMed:15032981}.
CC -!- DISEASE: Rickets vitamin D-dependent 2A (VDDR2A) [MIM:277440]: A
CC disorder of vitamin D metabolism resulting in severe rickets,
CC hypocalcemia and secondary hyperparathyroidism. Most patients have
CC total alopecia in addition to rickets. {ECO:0000269|PubMed:1652893,
CC ECO:0000269|PubMed:17970811, ECO:0000269|PubMed:2177843,
CC ECO:0000269|PubMed:2849209, ECO:0000269|PubMed:28698609,
CC ECO:0000269|PubMed:7828346, ECO:0000269|PubMed:8106618,
CC ECO:0000269|PubMed:8381803, ECO:0000269|PubMed:8392085,
CC ECO:0000269|PubMed:8675579, ECO:0000269|PubMed:8961271,
CC ECO:0000269|PubMed:9005998}. Note=The disease is caused by variants
CC affecting the gene represented in this entry.
CC -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC subfamily. {ECO:0000305}.
CC -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC {ECO:0000305}.
CC -!- CAUTION: Was thought to be recruited to promoters via its interaction
CC with BAZ1B/WSTF, but this work has later been retracted.
CC {ECO:0000305|PubMed:16252006, ECO:0000305|PubMed:25452584}.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAH60832.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC Sequence=AAP88938.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC URL="http://egp.gs.washington.edu/data/vdr/";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; J03258; AAA61273.1; -; mRNA.
DR EMBL; X67482; CAA47824.1; -; mRNA.
DR EMBL; AF026260; AAB95155.1; -; mRNA.
DR EMBL; AB002168; BAA83389.1; -; Genomic_DNA.
DR EMBL; AY342401; AAP88938.1; ALT_SEQ; Genomic_DNA.
DR EMBL; AK312267; BAG35198.1; -; mRNA.
DR EMBL; AC004466; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AC121338; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; CH471111; EAW57960.1; -; Genomic_DNA.
DR EMBL; CH471111; EAW57961.1; -; Genomic_DNA.
DR EMBL; BC060832; AAH60832.1; ALT_INIT; mRNA.
DR EMBL; M65208; AAA61274.1; -; mRNA.
DR EMBL; AY827087; AAV85448.1; -; Genomic_DNA.
DR CCDS; CCDS55820.1; -. [P11473-2]
DR CCDS; CCDS8757.1; -. [P11473-1]
DR PIR; A28200; A28200.
DR RefSeq; NP_000367.1; NM_000376.2. [P11473-1]
DR RefSeq; NP_001017535.1; NM_001017535.1. [P11473-1]
DR RefSeq; NP_001017536.1; NM_001017536.1. [P11473-2]
DR RefSeq; XP_006719650.1; XM_006719587.3.
DR RefSeq; XP_011537022.1; XM_011538720.2. [P11473-1]
DR PDB; 1DB1; X-ray; 1.80 A; A=118-427.
DR PDB; 1IE8; X-ray; 1.52 A; A=118-427.
DR PDB; 1IE9; X-ray; 1.40 A; A=118-427.
DR PDB; 1KB2; X-ray; 2.70 A; A/B=16-125.
DR PDB; 1KB4; X-ray; 2.80 A; A/B=16-125.
DR PDB; 1KB6; X-ray; 2.70 A; A/B=16-125.
DR PDB; 1S0Z; X-ray; 2.50 A; A=118-427.
DR PDB; 1S19; X-ray; 2.10 A; A=118-427.
DR PDB; 1TXI; X-ray; 1.90 A; A=118-427.
DR PDB; 1YNW; X-ray; 3.00 A; A=16-125.
DR PDB; 2HAM; X-ray; 1.90 A; A=118-427.
DR PDB; 2HAR; X-ray; 1.90 A; A=118-427.
DR PDB; 2HAS; X-ray; 1.96 A; A=118-427.
DR PDB; 2HB7; X-ray; 1.80 A; A=118-427.
DR PDB; 2HB8; X-ray; 2.00 A; A=118-427.
DR PDB; 3A2I; X-ray; 3.27 A; A=118-427.
DR PDB; 3A2J; X-ray; 2.70 A; A=118-427.
DR PDB; 3A3Z; X-ray; 1.72 A; X=118-427.
DR PDB; 3A40; X-ray; 1.45 A; X=118-427.
DR PDB; 3A78; X-ray; 1.90 A; A=118-427.
DR PDB; 3AUQ; X-ray; 2.64 A; A=118-427.
DR PDB; 3AUR; X-ray; 2.21 A; A=118-427.
DR PDB; 3AX8; X-ray; 2.60 A; A=118-427.
DR PDB; 3AZ1; X-ray; 1.50 A; A=120-423.
DR PDB; 3AZ2; X-ray; 1.69 A; A=120-423.
DR PDB; 3AZ3; X-ray; 1.36 A; A=120-423.
DR PDB; 3B0T; X-ray; 1.30 A; A=120-423.
DR PDB; 3CS4; X-ray; 2.00 A; A=118-427.
DR PDB; 3CS6; X-ray; 1.80 A; A=118-427.
DR PDB; 3KPZ; X-ray; 1.90 A; A=118-427.
DR PDB; 3M7R; X-ray; 1.80 A; A=120-423.
DR PDB; 3OGT; X-ray; 1.75 A; A=118-427.
DR PDB; 3P8X; X-ray; 1.70 A; A=118-164, A=217-427.
DR PDB; 3TKC; X-ray; 1.75 A; A=118-427.
DR PDB; 3VHW; X-ray; 2.43 A; A=118-427.
DR PDB; 3W0A; X-ray; 1.80 A; A=120-423.
DR PDB; 3W0C; X-ray; 1.90 A; A=120-423.
DR PDB; 3W0Y; X-ray; 1.98 A; A=120-423.
DR PDB; 3WGP; X-ray; 2.00 A; A=120-423.
DR PDB; 3WWR; X-ray; 3.18 A; A=118-427.
DR PDB; 3X31; X-ray; 2.11 A; A=118-427.
DR PDB; 3X36; X-ray; 1.93 A; A=118-427.
DR PDB; 4G2I; X-ray; 1.80 A; A=118-427.
DR PDB; 4ITE; X-ray; 2.49 A; A=118-427.
DR PDB; 4ITF; X-ray; 2.84 A; A=118-427.
DR PDB; 5GT4; X-ray; 1.83 A; A=118-423.
DR PDB; 5V39; X-ray; 2.20 A; A=119-425.
DR PDB; 5YSY; X-ray; 2.00 A; A=118-423.
DR PDB; 5YT2; X-ray; 2.00 A; A=118-423.
DR PDBsum; 1DB1; -.
DR PDBsum; 1IE8; -.
DR PDBsum; 1IE9; -.
DR PDBsum; 1KB2; -.
DR PDBsum; 1KB4; -.
DR PDBsum; 1KB6; -.
DR PDBsum; 1S0Z; -.
DR PDBsum; 1S19; -.
DR PDBsum; 1TXI; -.
DR PDBsum; 1YNW; -.
DR PDBsum; 2HAM; -.
DR PDBsum; 2HAR; -.
DR PDBsum; 2HAS; -.
DR PDBsum; 2HB7; -.
DR PDBsum; 2HB8; -.
DR PDBsum; 3A2I; -.
DR PDBsum; 3A2J; -.
DR PDBsum; 3A3Z; -.
DR PDBsum; 3A40; -.
DR PDBsum; 3A78; -.
DR PDBsum; 3AUQ; -.
DR PDBsum; 3AUR; -.
DR PDBsum; 3AX8; -.
DR PDBsum; 3AZ1; -.
DR PDBsum; 3AZ2; -.
DR PDBsum; 3AZ3; -.
DR PDBsum; 3B0T; -.
DR PDBsum; 3CS4; -.
DR PDBsum; 3CS6; -.
DR PDBsum; 3KPZ; -.
DR PDBsum; 3M7R; -.
DR PDBsum; 3OGT; -.
DR PDBsum; 3P8X; -.
DR PDBsum; 3TKC; -.
DR PDBsum; 3VHW; -.
DR PDBsum; 3W0A; -.
DR PDBsum; 3W0C; -.
DR PDBsum; 3W0Y; -.
DR PDBsum; 3WGP; -.
DR PDBsum; 3WWR; -.
DR PDBsum; 3X31; -.
DR PDBsum; 3X36; -.
DR PDBsum; 4G2I; -.
DR PDBsum; 4ITE; -.
DR PDBsum; 4ITF; -.
DR PDBsum; 5GT4; -.
DR PDBsum; 5V39; -.
DR PDBsum; 5YSY; -.
DR PDBsum; 5YT2; -.
DR AlphaFoldDB; P11473; -.
DR SMR; P11473; -.
DR BioGRID; 113264; 197.
DR ComplexPortal; CPX-631; RXRalpha-VDR nuclear hormone receptor complex.
DR ComplexPortal; CPX-871; RXRbeta-VDR nuclear hormone receptor complex.
DR CORUM; P11473; -.
DR DIP; DIP-32624N; -.
DR ELM; P11473; -.
DR IntAct; P11473; 34.
DR MINT; P11473; -.
DR STRING; 9606.ENSP00000447173; -.
DR BindingDB; P11473; -.
DR ChEMBL; CHEMBL1977; -.
DR DrugBank; DB07530; (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol.
DR DrugBank; DB08742; 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z).
DR DrugBank; DB01436; Alfacalcidol.
DR DrugBank; DB04891; Becocalcidiol.
DR DrugBank; DB00146; Calcifediol.
DR DrugBank; DB02300; Calcipotriol.
DR DrugBank; DB00136; Calcitriol.
DR DrugBank; DB00169; Cholecalciferol.
DR DrugBank; DB04540; Cholesterol.
DR DrugBank; DB05024; CTA018.
DR DrugBank; DB11672; Curcumin.
DR DrugBank; DB14635; Curcumin sulfate.
DR DrugBank; DB01070; Dihydrotachysterol.
DR DrugBank; DB06410; Doxercalciferol.
DR DrugBank; DB05295; Eldecalcitol.
DR DrugBank; DB06194; Elocalcitol.
DR DrugBank; DB00153; Ergocalciferol.
DR DrugBank; DB04796; Inecalcitol.
DR DrugBank; DB03451; Lexacalcitol.
DR DrugBank; DB00910; Paricalcitol.
DR DrugBank; DB04258; Seocalcitol.
DR DrugBank; DB11094; Vitamin D.
DR DrugCentral; P11473; -.
DR GuidetoPHARMACOLOGY; 605; -.
DR SwissLipids; SLP:000001571; -.
DR MoonDB; P11473; Predicted.
DR TCDB; 9.B.208.1.1; the vitamin d3 receptor (vdr) family.
DR iPTMnet; P11473; -.
DR PhosphoSitePlus; P11473; -.
DR BioMuta; VDR; -.
DR DMDM; 137617; -.
DR EPD; P11473; -.
DR jPOST; P11473; -.
DR MassIVE; P11473; -.
DR MaxQB; P11473; -.
DR PaxDb; P11473; -.
DR PeptideAtlas; P11473; -.
DR PRIDE; P11473; -.
DR ProteomicsDB; 32456; -.
DR ProteomicsDB; 52780; -. [P11473-1]
DR Antibodypedia; 3902; 818 antibodies from 44 providers.
DR DNASU; 7421; -.
DR Ensembl; ENST00000395324.6; ENSP00000378734.2; ENSG00000111424.12. [P11473-1]
DR Ensembl; ENST00000549336.6; ENSP00000449573.2; ENSG00000111424.12. [P11473-1]
DR Ensembl; ENST00000550325.5; ENSP00000447173.1; ENSG00000111424.12. [P11473-2]
DR GeneID; 7421; -.
DR KEGG; hsa:7421; -.
DR MANE-Select; ENST00000549336.6; ENSP00000449573.2; NM_000376.3; NP_000367.1.
DR UCSC; uc001rql.4; human. [P11473-1]
DR CTD; 7421; -.
DR DisGeNET; 7421; -.
DR GeneCards; VDR; -.
DR HGNC; HGNC:12679; VDR.
DR HPA; ENSG00000111424; Tissue enriched (parathyroid).
DR MalaCards; VDR; -.
DR MIM; 277440; phenotype.
DR MIM; 601769; gene.
DR MIM; 607948; phenotype.
DR neXtProt; NX_P11473; -.
DR OpenTargets; ENSG00000111424; -.
DR Orphanet; 93160; Hypocalcemic vitamin D-resistant rickets.
DR PharmGKB; PA37301; -.
DR VEuPathDB; HostDB:ENSG00000111424; -.
DR eggNOG; KOG3575; Eukaryota.
DR GeneTree; ENSGT00940000155473; -.
DR InParanoid; P11473; -.
DR OMA; CITSPDM; -.
DR OrthoDB; 297114at2759; -.
DR PhylomeDB; P11473; -.
DR TreeFam; TF316304; -.
DR PathwayCommons; P11473; -.
DR Reactome; R-HSA-196791; Vitamin D (calciferol) metabolism.
DR Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR SignaLink; P11473; -.
DR SIGNOR; P11473; -.
DR BioGRID-ORCS; 7421; 9 hits in 1090 CRISPR screens.
DR ChiTaRS; VDR; human.
DR EvolutionaryTrace; P11473; -.
DR GeneWiki; Calcitriol_receptor; -.
DR GenomeRNAi; 7421; -.
DR Pharos; P11473; Tclin.
DR PRO; PR:P11473; -.
DR Proteomes; UP000005640; Chromosome 12.
DR RNAct; P11473; protein.
DR Bgee; ENSG00000111424; Expressed in tibia and 150 other tissues.
DR ExpressionAtlas; P11473; baseline and differential.
DR Genevisible; P11473; HS.
DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR GO; GO:0005829; C:cytosol; IDA:HPA.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:BHF-UCL.
DR GO; GO:1902098; F:calcitriol binding; IDA:UniProtKB.
DR GO; GO:0003677; F:DNA binding; IDA:MGI.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR GO; GO:1902121; F:lithocholic acid binding; IDA:UniProtKB.
DR GO; GO:0038186; F:lithocholic acid receptor activity; IDA:UniProtKB.
DR GO; GO:0004879; F:nuclear receptor activity; IDA:UniProtKB.
DR GO; GO:0046965; F:nuclear retinoid X receptor binding; IDA:UniProtKB.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR GO; GO:0060057; P:apoptotic process involved in mammary gland involution; IEA:Ensembl.
DR GO; GO:0038183; P:bile acid signaling pathway; IDA:UniProtKB.
DR GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR GO; GO:0000902; P:cell morphogenesis; IMP:UniProtKB.
DR GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR GO; GO:0046697; P:decidualization; IEP:BHF-UCL.
DR GO; GO:0050892; P:intestinal absorption; IEA:Ensembl.
DR GO; GO:0007595; P:lactation; IEA:Ensembl.
DR GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:ComplexPortal.
DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:UniProtKB.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:MGI.
DR GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; IEA:Ensembl.
DR GO; GO:0030501; P:positive regulation of bone mineralization; IC:ComplexPortal.
DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IMP:UniProtKB.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ComplexPortal.
DR GO; GO:0010980; P:positive regulation of vitamin D 24-hydroxylase activity; IDA:BHF-UCL.
DR GO; GO:0070564; P:positive regulation of vitamin D receptor signaling pathway; IDA:ComplexPortal.
DR GO; GO:0060558; P:regulation of calcidiol 1-monooxygenase activity; ISS:BHF-UCL.
DR GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR GO; GO:0070561; P:vitamin D receptor signaling pathway; IDA:BHF-UCL.
DR CDD; cd06955; NR_DBD_VDR; 1.
DR DisProt; DP00184; -.
DR Gene3D; 1.10.565.10; -; 1.
DR Gene3D; 3.30.50.10; -; 1.
DR InterPro; IPR042153; DBD_VDR.
DR InterPro; IPR035500; NHR-like_dom_sf.
DR InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR InterPro; IPR000324; VitD_rcpt.
DR InterPro; IPR001628; Znf_hrmn_rcpt.
DR InterPro; IPR013088; Znf_NHR/GATA.
DR Pfam; PF00104; Hormone_recep; 1.
DR Pfam; PF00105; zf-C4; 1.
DR PRINTS; PR00398; STRDHORMONER.
DR PRINTS; PR00047; STROIDFINGER.
DR PRINTS; PR00350; VITAMINDR.
DR SMART; SM00430; HOLI; 1.
DR SMART; SM00399; ZnF_C4; 1.
DR SUPFAM; SSF48508; SSF48508; 1.
DR PROSITE; PS51843; NR_LBD; 1.
DR PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Cytoplasm; Disease variant;
KW DNA-binding; Metal-binding; Nucleus; Receptor; Reference proteome;
KW Transcription; Transcription regulation; Zinc; Zinc-finger.
FT CHAIN 1..427
FT /note="Vitamin D3 receptor"
FT /id="PRO_0000053542"
FT DOMAIN 127..423
FT /note="NR LBD"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT DNA_BIND 21..96
FT /note="Nuclear receptor"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT ZN_FING 24..44
FT /note="NR C4-type"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT ZN_FING 60..84
FT /note="NR C4-type"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT REGION 97..126
FT /note="Hinge"
FT /evidence="ECO:0000269|PubMed:10678179"
FT REGION 158..190
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 246..264
FT /note="Interaction with coactivator LXXLL motif"
FT /evidence="ECO:0000250|UniProtKB:P13053"
FT MOTIF 416..424
FT /note="9aaTAD"
FT /evidence="ECO:0000269|PubMed:30468856"
FT COMPBIAS 165..190
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT BINDING 143
FT /ligand="calciol"
FT /ligand_id="ChEBI:CHEBI:28940"
FT /evidence="ECO:0000269|PubMed:10678179,
FT ECO:0000269|PubMed:11344298"
FT BINDING 227..237
FT /ligand="calciol"
FT /ligand_id="ChEBI:CHEBI:28940"
FT /evidence="ECO:0000269|PubMed:10678179,
FT ECO:0000269|PubMed:11344298"
FT BINDING 271..278
FT /ligand="calciol"
FT /ligand_id="ChEBI:CHEBI:28940"
FT /evidence="ECO:0000269|PubMed:10678179,
FT ECO:0000269|PubMed:11344298"
FT BINDING 305
FT /ligand="calciol"
FT /ligand_id="ChEBI:CHEBI:28940"
FT /evidence="ECO:0000269|PubMed:10678179,
FT ECO:0000269|PubMed:11344298"
FT BINDING 397
FT /ligand="calciol"
FT /ligand_id="ChEBI:CHEBI:28940"
FT /evidence="ECO:0000269|PubMed:10678179,
FT ECO:0000269|PubMed:11344298"
FT VAR_SEQ 1
FT /note="M -> MEWRNKKRSDWLSMVLRTAGVEEAFGSEVSVRPHRRAPLGSTYLPPA
FT PSGM (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_047218"
FT VARIANT 33
FT /note="G -> D (in VDDR2A; dbSNP:rs121909790)"
FT /evidence="ECO:0000269|PubMed:2849209"
FT /id="VAR_004656"
FT VARIANT 35
FT /note="H -> Q (in VDDR2A)"
FT /evidence="ECO:0000269|PubMed:8381803"
FT /id="VAR_004657"
FT VARIANT 45
FT /note="K -> E (in VDDR2A)"
FT /evidence="ECO:0000269|PubMed:7828346"
FT /id="VAR_004658"
FT VARIANT 46
FT /note="G -> D (in VDDR2A; dbSNP:rs121909797)"
FT /evidence="ECO:0000269|PubMed:8675579"
FT /id="VAR_004659"
FT VARIANT 47
FT /note="F -> I (in VDDR2A)"
FT /evidence="ECO:0000269|PubMed:7828346"
FT /id="VAR_004660"
FT VARIANT 50
FT /note="R -> Q (in VDDR2A; dbSNP:rs121909794)"
FT /evidence="ECO:0000269|PubMed:1652893"
FT /id="VAR_004661"
FT VARIANT 73
FT /note="R -> Q (in VDDR2A; dbSNP:rs121909791)"
FT /evidence="ECO:0000269|PubMed:2849209"
FT /id="VAR_004662"
FT VARIANT 80
FT /note="R -> Q (in VDDR2A; dbSNP:rs121909793)"
FT /evidence="ECO:0000269|PubMed:2177843,
FT ECO:0000269|PubMed:8106618"
FT /id="VAR_004663"
FT VARIANT 152..427
FT /note="Missing (in VDDR2A; loss of calcitriol receptor
FT activity; loss of affinity for calcitriol; no effect on
FT ligand-independent localization to the nucleus;
FT dbSNP:rs121909795)"
FT /evidence="ECO:0000269|PubMed:28698609,
FT ECO:0000269|PubMed:8392085"
FT /id="VAR_079325"
FT VARIANT 230
FT /note="L -> V (in dbSNP:rs11574090)"
FT /evidence="ECO:0000269|Ref.5"
FT /id="VAR_029309"
FT VARIANT 274
FT /note="R -> L (in VDDR2A; loss of calcitriol receptor
FT activity; decreased affinity for calcitriol by a factor of
FT 1000; no effect on interaction with RXRA; changed
FT interaction with NCOR1; loss of interaction with NCOA1; no
FT effect on sequence-specific DNA-binding;
FT dbSNP:rs121909796)"
FT /evidence="ECO:0000269|PubMed:28698609,
FT ECO:0000269|PubMed:8392085"
FT /id="VAR_004664"
FT VARIANT 305
FT /note="H -> Q (in VDDR2A; loss of calcitriol receptor
FT activity; no effect on interaction with RXRA; changed
FT interaction with NCOR1; loss of interaction with NCOA1; no
FT effect on sequence-specific DNA-binding;
FT dbSNP:rs121909798)"
FT /evidence="ECO:0000269|PubMed:28698609,
FT ECO:0000269|PubMed:9005998"
FT /id="VAR_004665"
FT VARIANT 314
FT /note="I -> S (in VDDR2A; dbSNP:rs121909799)"
FT /evidence="ECO:0000269|PubMed:8961271"
FT /id="VAR_004666"
FT VARIANT 346
FT /note="V -> M (in VDDR2A; decreased calcitriol receptor
FT activity; decreased affinity for calcitriol; decreased
FT ligand-independent localization to the nucleus; loss of
FT interaction with RXRA; decreased interaction with NCOR1;
FT decreased interaction with NCOA1; decreased sequence-
FT specific DNA-binding; dbSNP:rs267607169)"
FT /evidence="ECO:0000269|PubMed:17970811,
FT ECO:0000269|PubMed:28698609"
FT /id="VAR_079326"
FT VARIANT 360
FT /note="S -> P (in VDDR2A; loss of calcitriol receptor
FT activity; loss of affinity for calcitriol; decreased
FT ligand-independent localization to the nucleus; loss of
FT interaction with RXRA; loss of interaction with NCOR1; loss
FT of interaction with NCOA1; loss of sequence-specific DNA-
FT binding)"
FT /evidence="ECO:0000269|PubMed:28698609"
FT /id="VAR_079327"
FT VARIANT 362
FT /note="T -> I (in dbSNP:rs11574115)"
FT /evidence="ECO:0000269|Ref.5"
FT /id="VAR_029310"
FT VARIANT 391
FT /note="R -> C (in VDDR2A; dbSNP:rs121909800)"
FT /evidence="ECO:0000269|PubMed:8961271"
FT /id="VAR_004667"
FT MUTAGEN 47..48
FT /note="FF->AA: Abolishes nuclear export."
FT /evidence="ECO:0000269|PubMed:12145331"
FT MUTAGEN 61..62
FT /note="PF->AA: Promotes heterodimerization with RXRA; when
FT associated with A-75."
FT /evidence="ECO:0000269|PubMed:11980721"
FT MUTAGEN 75
FT /note="H->A: Promotes heterodimerization with RXRA; when
FT associated with A-61 and A-62."
FT /evidence="ECO:0000269|PubMed:11980721"
FT TURN 25..27
FT /evidence="ECO:0007829|PDB:1KB2"
FT STRAND 33..35
FT /evidence="ECO:0007829|PDB:1KB2"
FT STRAND 38..40
FT /evidence="ECO:0007829|PDB:1KB6"
FT HELIX 42..53
FT /evidence="ECO:0007829|PDB:1KB2"
FT STRAND 61..64
FT /evidence="ECO:0007829|PDB:1KB4"
FT TURN 70..75
FT /evidence="ECO:0007829|PDB:1KB2"
FT HELIX 77..86
FT /evidence="ECO:0007829|PDB:1KB2"
FT HELIX 91..93
FT /evidence="ECO:0007829|PDB:1KB2"
FT HELIX 97..107
FT /evidence="ECO:0007829|PDB:1KB2"
FT STRAND 108..110
FT /evidence="ECO:0007829|PDB:1KB6"
FT TURN 111..113
FT /evidence="ECO:0007829|PDB:1KB6"
FT HELIX 115..119
FT /evidence="ECO:0007829|PDB:1KB6"
FT HELIX 126..142
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 150..152
FT /evidence="ECO:0007829|PDB:3B0T"
FT TURN 162..164
FT /evidence="ECO:0007829|PDB:5V39"
FT HELIX 217..223
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 227..247
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 251..253
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 256..274
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 275..277
FT /evidence="ECO:0007829|PDB:3B0T"
FT TURN 281..284
FT /evidence="ECO:0007829|PDB:3B0T"
FT STRAND 285..287
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 291..293
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 297..301
FT /evidence="ECO:0007829|PDB:3B0T"
FT TURN 302..304
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 307..321
FT /evidence="ECO:0007829|PDB:3B0T"
FT TURN 322..324
FT /evidence="ECO:0007829|PDB:2HAR"
FT HELIX 327..338
FT /evidence="ECO:0007829|PDB:3B0T"
FT STRAND 341..343
FT /evidence="ECO:0007829|PDB:3AUQ"
FT HELIX 349..370
FT /evidence="ECO:0007829|PDB:3B0T"
FT TURN 373..378
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 379..404
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 410..413
FT /evidence="ECO:0007829|PDB:3B0T"
FT HELIX 416..422
FT /evidence="ECO:0007829|PDB:3B0T"
SQ SEQUENCE 427 AA; 48289 MW; F95F300D042C4CB7 CRC64;
MEAMAASTSL PDPGDFDRNV PRICGVCGDR ATGFHFNAMT CEGCKGFFRR SMKRKALFTC
PFNGDCRITK DNRRHCQACR LKRCVDIGMM KEFILTDEEV QRKREMILKR KEEEALKDSL
RPKLSEEQQR IIAILLDAHH KTYDPTYSDF CQFRPPVRVN DGGGSHPSRP NSRHTPSFSG
DSSSSCSDHC ITSSDMMDSS SFSNLDLSEE DSDDPSVTLE LSQLSMLPHL ADLVSYSIQK
VIGFAKMIPG FRDLTSEDQI VLLKSSAIEV IMLRSNESFT MDDMSWTCGN QDYKYRVSDV
TKAGHSLELI EPLIKFQVGL KKLNLHEEEH VLLMAICIVS PDRPGVQDAA LIEAIQDRLS
NTLQTYIRCR HPPPGSHLLY AKMIQKLADL RSLNEEHSKQ YRCLSFQPEC SMKLTPLVLE
VFGNEIS
